At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 153 enrolled
Drug / intervention
bermekimab +1 moredrug
Likely dose
bermekimab 2 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa
In Brief
A Phase 2 clinical trial evaluating bermekimab and placebo for Hidradenitis Suppurativa and 2 related conditions. Completed, enrolled 153 participants across 33 sites.
Detailed Summary
This study further evaluates the efficacy of bermekimab in treating moderate to severe hidradenitis suppurativa in adults. 1/3 of patients will receive weekly injections of bermekimab, 1/3 will receive alternating every other week injections of bermekimab or placebo, and 1/3 will receive weekly injections of placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJul 2019
Enrollment StartSep 2019
Primary CompletionMay 2020
Study CompletionNov 2020
TodayJul 2026
First PostedJul 15, 2019
Enrollment StartSep 16, 2019
Primary CompletionMay 19, 2020
Study CompletionNov 17, 2020
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 7.0 years ago
Interventions
bermekimabdrug
bermekimab 2 mL (200 mg/mL) pre-filled syringe
placebodrug
placebo 2 mL pre-filled syringe